Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Studied

A double-blind randomized trial compared tesamorelin with placebo for six months. Primary outcomes were visceral abdominal fat and liver fat.

Who / model

50 adults with HIV receiving antiretroviral treatment and with abdominal-fat accumulation were randomized; forty-eight received study treatment.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Visceral-fat area fell by 34 square centimeters with tesamorelin versus an increase of 8 with placebo. The liver lipid-to-water percentage fell 2.0 percentage points versus a 0.9-point increase. Fasting glucose rose initially at two weeks, but six-month fasting and two-hour glucose changes did not significantly differ.

Limits

The authors described the findings as preliminary and said further studies were needed to determine their clinical importance and long-term consequences.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary